Fertility and pregnancy on immunotherapy — what is known, and what is not

Pregnancy should be avoided during immunotherapy. It is physically possible, because these medicines do not reliably stop ovulation, and that is precisely why contraception matters. The immune pathway that checkpoint inhibitor immunotherapy blocks is one the body uses to tolerate a pregnancy, so the risk to a pregnancy is treated as real, not theoretical.

Before going further, one thing has to be said plainly, because it saves a great many young women a month of worry. Most breast cancer patients are not candidates for immunotherapy at all. It has a defined role in a minority of breast cancers, mainly triple-negative disease, and in gynaecological cancers it is used in specific situations decided by biomarker testing rather than offered to everyone. If immunotherapy is not in your plan, the timings on this page do not apply to you. The fertility conversation still does, because chemotherapy and radiation therapy affect fertility far more directly than immunotherapy is known to.

Where immunotherapy is part of the plan, the reasoning behind the pregnancy advice is worth understanding rather than simply obeying. Checkpoint inhibitors work by releasing a brake on the immune system. One of the jobs that same brake does in the body is to stop a pregnant woman’s immune system from rejecting a fetus, which is genetically half someone else’s. Loosening that brake during pregnancy is not something anyone has been willing to test deliberately, and the approved product information for these medicines reflects that.

So this page will not tell you that immunotherapy is safe in pregnancy, and it will not tell you that it definitely harms fertility either. Both would be overstating what is known. What it will do is set out what the product information says, what the mechanism suggests, what your treating team can actually decide, and which questions to ask before the first cycle. At CION, immunotherapy is given as day care at our centres when it is genuinely indicated, every plan is set by a tumour board rather than by one doctor, and any cost discussed with you is indicative, as of August 2026, and confirmed in writing.

Nobody knows yet, and it is more useful to say so. Immunotherapy is not known to damage eggs or sperm the way chemotherapy can, because it does not work by killing dividing cells. But these medicines are recent, most people who received them were past childbearing age, and long-term human fertility data do not exist.

There is one plausible indirect route, and it is worth knowing about because it is manageable. Immune-related side effects can involve the pituitary, thyroid and adrenal glands. Those glands run the hormone signals that control periods and ovulation, so an inflamed pituitary or an underactive thyroid can disturb a cycle without anything having happened to the ovaries themselves. Some of these effects settle. Some need hormone replacement for life. Either way, they are picked up on the blood tests done before each cycle, which is one reason those tests are not optional.

The larger point is that in breast and gynaecological cancers, immunotherapy is almost never given on its own. It is usually added to chemotherapy, and chemotherapy’s effect on the ovaries is far better documented. Radiation to the pelvis and some surgery carry their own risks. So the practical question is rarely “what does immunotherapy alone do to my fertility?” — it is “what does this whole plan do, and what can be preserved before it starts?”

• What can fairly be said — immunotherapy does not act on rapidly dividing cells, so the direct ovarian damage seen with some chemotherapy is not expected from it.
• What cannot be said — that it is proven safe for fertility. Guideline bodies including ASCO and ESMO describe the evidence in this age group as limited.
• What is known to matter — the chemotherapy, radiation therapy or surgery given alongside it, and your age when treatment starts.
• What is worth testing — thyroid, pituitary and adrenal function if periods stop or change, because an immune-related endocrine effect is treatable.
• What has to happen first — fertility preservation is discussed before treatment begins. Your oncologist can refer you to a reproductive medicine specialist; the referral is arranged from the clinic, and CION does not itself provide fertility treatment.

If you are in your twenties or thirties and have just been told you need treatment, ask about fertility at the very first consultation, even if you are unsure whether you want children. Options narrow quickly once treatment starts, and a delay of a week or two for fertility preservation is often possible where a delay of three months is not. It is a question you are entitled to ask, and no oncologist should treat it as a distraction.

There is no single agreed number. The minimum is the contraception period carried in the approved product information for the medicine you received, commonly at least four to five months after the last dose. Beyond that minimum, the wait depends on your cancer, the rest of your plan, and your oncologist’s advice.

The four-to-five month figure is the contraception advice carried in approved product information for this class of medicine and registered with regulators including the CDSCO in India. It is a precaution based on how long the medicine stays active in the body, not a fertility recommendation, and it is the shortest possible answer rather than the right one for you. Ask for your own waiting period in writing, with the date of your last dose on it, and take that letter to whoever advises you on pregnancy afterwards. Our page on contraception during immunotherapy goes through the practical side in more detail.

Tell your oncology team the same day. Do not stop treatment on your own, and do not wait for the next cycle to mention it. Your team will pause or change the plan, involve an obstetrician, and go through the options with you. This is an immediate conversation, not a private one.

Two things make the same-day part important. The first is that stopping a treatment abruptly without medical advice can carry its own risks, and the plan needs to be changed properly rather than simply abandoned. The second is that the useful options narrow with time, and every one of them needs an obstetrician in the room alongside the oncologist.

Be prepared for the fact that nobody will be able to give you a reliable number. What is known about pregnancies exposed to checkpoint inhibitors comes from scattered case reports, not from any controlled study, and guideline bodies say as much. That is genuinely unsatisfying, and it is still better than a confident figure that has nothing behind it. Treat any source that quotes you a precise risk percentage for this situation with caution.

What you should expect from your team is time, a clear explanation of what is known and unknown, an obstetric opinion, and no pressure in either direction. The decision that follows is yours. Nothing about the situation is a reason to feel judged, and the only thing that reliably makes it harder is delaying the conversation.

Reliable contraception is expected from before the first dose until at least the period stated in the product information after the last dose. Choose a method with your oncologist rather than alone, because your cancer type and your blood counts both affect which options are sensible during treatment.

1. 1

   Raise it before the first cycle

   Your oncologist should ask, but ask anyway. Contraception, fertility preservation and breastfeeding all belong in the same conversation, and all three are easier to act on before treatment starts than after.

2. 2

   Get the exact end date in writing

   Ask for the date of your planned last dose and the number of months of contraception advised after it, on paper. The advice differs between medicines, and a general figure from the internet is not your figure.

3. 3

   Pick a method that fits the plan, not just the month

   Hormone-containing methods are usually avoided in hormone receptor positive breast cancer. Low platelet counts or a raised infection risk can affect the choice at particular points in treatment. This is an oncologist’s decision with you, not a pharmacy counter decision.

4. 4

   Keep using it even if your periods stop

   Periods stopping during treatment does not mean you have become infertile. Ovulation can return without warning, sometimes before the periods do. Contraception continues until your oncologist and a fertility specialist say otherwise.

5. 5

   Include your partner in the conversation

   Advice for male patients on immunotherapy is less settled than the advice for women, and where a partner is also receiving cancer treatment there may be separate timing to consider. Ask rather than assume it does not apply.

None of this is a judgement about whether you should have children. It is the opposite: contraception during treatment is what protects the option of a healthy pregnancy later, at a point when the treatment can no longer affect it. Costs of any preservation step or specialist referral are indicative, as of August 2026, and should be given to you in writing before anything is booked.

Breastfeeding is advised against during immunotherapy and for a period after the last dose, because it is not known how much passes into breast milk. Male fertility data are thinner still. In both cases the advice is precautionary and reflects missing evidence rather than proven harm.

Breastfeeding. If you are feeding an infant when treatment is planned, say so before the first cycle. The restriction usually extends for some months past the last dose, the exact period differs by medicine, and it should be given to you in writing along with the contraception advice. Where feeding matters a great deal to a family, the timing of treatment is sometimes the thing that can be discussed, and that is a conversation worth having openly.

Male patients. Advice here is less settled. Some product information extends contraception advice to men receiving treatment; some does not. What is consistent is that chemotherapy given alongside immunotherapy can affect sperm, and that sperm banking, where it is relevant, has to happen before treatment starts. Ask your oncologist what the product information for your specific medicine says rather than assuming the advice is only for women.

The long term. Whether immunotherapy has any effect on a pregnancy conceived long after treatment has finished, or on a child born from it, is not known. These medicines have not been in use long enough for that question to have an evidence-based answer, and the same is true of long-term immune-related side effects generally. Anyone who tells you otherwise is guessing. What your team can do is make sure your hormones, thyroid and general health are stable and reviewed before you try, which is the part that is actually within anyone’s control.

Most of the anxiety here comes from not knowing which parts of the advice apply to you. These six questions get you a complete answer in a single consultation, whichever way it goes.

• Is immunotherapy actually part of my plan, or was it only discussed as a possibility?
• Which parts of my plan are known to affect fertility, and how much of that is the chemotherapy rather than the immunotherapy?
• Can fertility preservation be done before treatment starts, and who would I be referred to?
• What contraception do you advise, from when, and until how many months after my last dose — in writing?
• If I want to try for a pregnancy afterwards, what is the earliest you would be comfortable with, and what would you want checked first?
• What would the full plan cost, and does Aarogyasri, CGHS, ECHS, ESI or my insurance cover any part of it?

Related reading

• Contraception During Immunotherapy: Why It Is Non-Negotiable — the practical companion to this page, covering methods, timing and what to do about a missed dose.
• Cost of Immunotherapy for Breast and Gynaecological Cancers — indicative costs, what schemes and insurance typically cover, and what to get in writing before starting.
• Immunotherapy for Small Cell Lung Cancer — useful for the principle, showing how eligibility and timing are decided in a different cancer where immunotherapy is used more widely.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, how response scans are coordinated with our partner imaging centres, and how costs are set out in writing.

CION is a woman-headed organisation, and a large share of the patients our teams see are women being treated for breast and gynaecological cancers. Every consultation is 45 minutes, every plan goes to a tumour board, and the fertility question is one we would rather you asked us on day one than searched for at midnight.

This page is general information and does not replace a consultation. It describes treatment classes only, not specific medicines or brands, and it recommends no treatment. Contraception and breastfeeding periods are drawn from approved product information for checkpoint inhibitor medicines registered with regulators including the CDSCO, and from NCCN, ASCO and ESMO patient-education guidance current in August 2026; they differ between medicines and can change. Evidence on fertility, pregnancy outcomes and long-term effects in this setting is limited, and no outcome or survival figure of any kind is stated or implied. Every decision about your treatment belongs with your own treating team.

Get a second opinion before the first cycle

Free, written and reviewed by our tumour board — so you know what is in your plan, what it means for fertility, and what has to be decided first.